Compare

Follistatin 344 vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Follistatin 344

6 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 100% · Mixed 0% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
6
Sleep
6
Energy
3

Self-reported dose per injection

Median bucket: 50–100 mcg · Most common: 50–100 mcg

Reports span 50–200 mcg

50–100
4
100–200
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Commonly stacked with

Tirzepatide

7 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 14% · Mixed 0% · Unfavorable overall 86%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
7
Sleep
1
Mood
1
Energy
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
3
Injection site irritation
3

Self-reported dose per injection

Median bucket: 5+ mg · Most common: 5+ mg

Reports span 0.4 to ≥ 5 mg (open-ended top bucket)

0.4–0.6 mg
1
5+ mg
6

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Sources (15)

Published sources linked on the Follistatin 344 and Tirzepatide wiki pages.

  1. PubMed

    Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

    Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009

    Source
    Wiki study page →
  2. ClinicalTrials.gov

    Follistatin / Myostatin inhibition studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  3. PubMed

    Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis

    Sugiyama M, Yamaki A, Furuya M, et al. American Journal of Physiology — Endocrinology and Metabolism. 2010

    Source
    Wiki study page →
  4. PubMed

    Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy

    Sepulveda PV, Bush ED, Bhattacharya A, et al. Scientific Reports. 2015

    Source
    Wiki study page →
  5. PubMed

    The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation

    Stefanakis K, Kokkorakis M, Mantzoros CS. Metabolism: clinical and experimental. 2024

    Source
    Wiki study page →
  6. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  7. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  11. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  12. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  13. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  14. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  15. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →